• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BIAF

    bioAffinity Technologies Inc.

    Subscribe to $BIAF
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IPO Year: 2022

    Exchange: NASDAQ

    Recent Analyst Ratings for bioAffinity Technologies Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    bioAffinity Technologies Inc. SEC Filings

    See more
    • bioAffinity Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/25/25 4:15:56 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/23/25 4:30:48 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/22/25 4:30:55 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/15/25 4:15:27 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by bioAffinity Technologies Inc.

      EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/7/25 12:15:09 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by bioAffinity Technologies Inc.

      EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/7/25 12:15:16 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:53:08 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:50:32 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by bioAffinity Technologies Inc.

      DEFA14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/2/25 5:29:21 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEF 14A filed by bioAffinity Technologies Inc.

      DEF 14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/2/25 5:28:55 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    bioAffinity Technologies Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools

      bioAffinity Technologies' noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a compelling new case study in which CyPath® Lung identified a Stage 1A neuroendocrine tumor in the patient's lung after PET scan, bronchoscopies and a serum tumor marker test suggested it was non-cancerous inflammation. "We believe that this patient's experience demonstrates the high added value that CyPath® Lung brings to the diagnostic pathway. Multiple procedures and diagnostic tools were incon

      7/23/25 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

      New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian

      7/22/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

      One third of world's smokers live in China, which has highest rate of lung cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. China represents a large prospective market for CyPath® Lung with more than 300 million people who smoke, or a third of the world's total smokers, according to th

      7/15/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging

      bioAffinity Technologies' noninvasive sputum test revealed early-stage lung cancer when other diagnostic options were contraindicated bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in a patient whose PET imaging and risk model probability indicated a low risk of malignancy. "CyPath® Lung gave us the critical data point we were missing. This patient had all the red flags – heavy tobacco use, COPD and a suspicious nodule – but imaging and ri

      7/9/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company's recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration. The presentation at the 2025 RNA Therapeutics Conference, titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas," highlights a novel therapeutic approach that uses small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting tw

      6/26/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

      Company research targets topical application for treatment of skin cancers bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs

      6/24/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced publication of "The Drive for Early Detection," a case study detailing how bioAffinity Technologies utilizes support from Cardinal Health™ OptiFreight® Logistics to help meet demand for CyPath® Lung, a noninvasive test for detection of early stage lung cancer. "Our innovative, accurate diagnostic for lung cancer relies on dependable, on-time delivery of viable sputum samples to our laboratory for processing and providing reliable results to patients and their physicians," bioAffinity President and CEO Maria Zannes said. "CyPa

      6/3/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

      Simultaneous siRNA Knockdown of Specific Cell Receptors Shown to Selectively Kill Cancer Company Research Targets Topical Application for Treatment of Skin Cancers bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering a novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The patent, "Compositions and Methods for Treating Cancer," (Patent No. 12,305,171) provides for use of the novel therapeutic approach with cancers of the lung

      5/28/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

      5/20/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    bioAffinity Technologies Inc. Leadership Updates

    Live Leadership Updates

    See more
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

      5/20/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

      Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi

      11/4/24 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath® Lung, the Company's noninvasive test to detect early-stage lung cancer. Reported accelerating growth of 350% in CyPath® Lung tests ordered and processed in Q1 2024 as

      4/1/24 9:49:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective Dec. 1, 2023. Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets. "Dr. Platt's impressive track record in transforming research organizations into successful commercial entities, her commitment to operational excellence and innovation, and her extensive experience in expanding product market share in the diagnostics market make her a valuable asset to our team as we move forward

      12/5/23 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership with the American Cancer Society (ACS) to increase lung cancer screening in Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231115775728/en/A partnership to improve lung cancer screening. (Graphic: Business Wire) "The Power of Three" campaign emphasizes the importance of joining forces in the fight against lung cancer by supporting local programs like the Quality Improvement Program to Increase Lu

      11/15/23 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales. Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America's therapeutic solutions division. Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities. "We are delighted

      11/6/23 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications

      Company enlists Havas Health & You, Trinity Life Sciences to help build CyPath® Lung brand bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies' Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector. CyPath® Lung is a non-invasive test that detects early-stage lung cancer by automated flow cytometry and machine learnin

      2/13/23 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    bioAffinity Technologies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by bioAffinity Technologies Inc.

      SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)

      10/10/23 6:03:06 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    bioAffinity Technologies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Reveles Xavier Trinidad was granted 21,604 shares, increasing direct ownership by 106% to 41,943 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:26 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Secretary, EVP, Gen. Counsel Zannes Timothy P was granted 8,641 shares, increasing direct ownership by 19% to 54,765 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:20 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • President & CEO Zannes Maria was granted 37,037 shares, increasing direct ownership by 15% to 280,359 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:23 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Executive Chairman Girgenti Steven was granted 14,814 shares, increasing direct ownership by 1% to 1,080,062 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:24 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • VP and CFO Edwards James Michael was granted 6,172 shares, increasing direct ownership by 5% to 120,128 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:21 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • VP and CFO Edwards James Michael was granted 100,000 shares, increasing direct ownership by 717% to 113,956 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      11/5/24 7:05:50 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • New insider Edwards James Michael claimed ownership of 13,956 shares (SEC Form 3)

      3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      9/20/24 5:01:37 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Diamond Stuart was granted 33,784 shares, increasing direct ownership by 52% to 99,088 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      7/2/24 6:47:14 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Executive Chairman Girgenti Steven was granted 33,784 shares, increasing direct ownership by 3% to 1,065,248 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      7/2/24 6:47:13 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Rubin Gary D was granted 33,784 shares, increasing direct ownership by 30% to 146,597 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      7/2/24 6:47:07 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    bioAffinity Technologies Inc. Financials

    Live finance-specific insights

    See more
    • Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

      1/10/25 9:00:00 AM ET
      $BIAF
      $ENLV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

      7/12/24 9:35:00 AM ET
      $BIAF
      $BTCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
    • BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target

      7/5/24 9:00:00 AM ET
      $BIAF
      $BIVI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloombe

      1/5/24 9:00:00 AM ET
      $BIAF
      $BIVI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

      Transformative Strategic Transaction Supports Commercialization of CyPath® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity's Board of Directors Conference Call at 4:30 p.m. Eastern time Today bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. The laboratory assets are being acquire

      9/19/23 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

      Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions. Event:       bioAffinity Technologies Fourth Quarter 2022 Financial Results Date:       Monday, April 3, 2023 Time:       9:00 a.m. EDT Toll Free:       1-877-270-2148 International:       1-412-902-6510 Webcast:       Webcast link A replay o

      3/24/23 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care